23.75

1.29% -0.31

After Hours: 23.75

Pacira Biosciences Inc (PCRX)

Overview News Price History Option Chain Financials Discussions Forecast

Pacira Biosciences Inc stock is traded at $23.75, with a volume of 307.06K. It is down -1.29% in the last 24 hours and up +2.11% over the past month. Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Previous Close:

$24.06

Open:

$23.95

24h Volume:

307.06K

Relative Volume:

0.37

Market Cap:

$961.63M

Revenue:

$726.41M

Net Income/Loss:

$7.03M

P/E Ratio:

151.18

EPS:

0.1571

Net Cash Flow:

$136.66M

1W Performance:

+5.42%

1M Performance:

+2.11%

6M Performance:

+4.49%

1Y Performance:

-4.89%

1-Day Range:

$23.69

$24.38

1-Week Range:

$22.75

$24.38

52-Week Range:

$18.80

$27.98

Pacira Biosciences Inc Stock (PCRX) Company Profile

Name

Pacira Biosciences Inc

Sector

Healthcare (1110)

Industry

Drug Manufacturers - Specialty & Generic (83)

Phone

650-242-8052

Address

2000 SIERRA POINT PARKWAY, BRISBANE, NJ

Employee

829

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

PCRX's Discussions on Twitter

Compare PCRX vs TAK, ZTS, HLN, TEVA, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PCRX Pacira Biosciences Inc	23.75	963.25M	726.41M	7.03M	136.66M	0.1571
TAK Takeda Pharmaceutical Co Adr	17.85	57.12B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	121.11	49.56B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	9.70	43.86B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	31.77	35.89B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	578.54	25.06B	3.18B	1.33B	1.04B	27.90

Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-09-25	Initiated	Barclays	Equal Weight
Nov-17-25	Initiated	H.C. Wainwright	Buy
Jul-25-25	Upgrade	Truist	Hold → Buy
Jan-30-25	Upgrade	Truist	Sell → Hold
Aug-13-24	Downgrade	Truist	Buy → Sell
Aug-12-24	Downgrade	JP Morgan	Overweight → Underweight
Aug-12-24	Downgrade	Piper Sandler	Overweight → Neutral
Aug-12-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Aug-12-24	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-03-24	Downgrade	Barclays	Overweight → Equal Weight
Mar-07-24	Resumed	JP Morgan	Overweight
Dec-20-23	Initiated	Raymond James	Outperform
Aug-03-23	Upgrade	TD Cowen	Market Perform → Outperform
Jan-31-23	Resumed	Wedbush	Outperform
Oct-21-22	Resumed	Jefferies	Buy
Jan-03-22	Resumed	JP Morgan	Overweight
Jul-26-21	Upgrade	JP Morgan	Neutral → Overweight
Apr-21-21	Resumed	JP Morgan	Neutral
Apr-09-21	Initiated	Berenberg	Buy
Apr-07-21	Resumed	RBC Capital Mkts	Outperform
Feb-11-21	Downgrade	Northland Capital	Outperform → Market Perform
Jan-21-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Sep-21-20	Upgrade	Northland Capital	Market Perform → Outperform
Jul-06-20	Reiterated	Needham	Buy
May-27-20	Initiated	Guggenheim	Neutral
Apr-07-20	Initiated	Northland Capital	Outperform
Mar-20-20	Upgrade	SVB Leerink	Mkt Perform → Outperform
Feb-24-20	Reiterated	H.C. Wainwright	Buy
Jan-24-20	Initiated	SunTrust	Buy
Jan-23-20	Initiated	SunTrust	Buy
Nov-06-19	Initiated	BTIG Research	Buy
Jun-11-19	Initiated	Barclays	Overweight
May-06-19	Upgrade	Mizuho	Underperform → Neutral
May-02-19	Upgrade	Stifel	Sell → Hold
Feb-01-19	Downgrade	Mizuho	Neutral → Underperform
Aug-06-18	Downgrade	BofA/Merrill	Buy → Neutral
Apr-09-18	Reiterated	H.C. Wainwright	Buy
Mar-21-18	Reiterated	Mizuho	Neutral
Feb-16-18	Downgrade	Needham	Buy → Hold
Jan-19-18	Initiated	Seaport Global Securities	Buy
Jan-04-18	Reiterated	Canaccord Genuity	Buy
Jan-03-18	Initiated	Leerink Partners	Mkt Perform

View All

Pacira Biosciences Inc Stock (PCRX) Latest News

Apr 13, 2026

Pacira (PCRX) Data Highlights Cost Benefits and Opioid Reduction - GuruFocus

Apr 13, 2026

Pacira BioSciences, Inc. Presents Real-World Data On EXPAREL Showing Lower Total Healthcare Costs In Outpatient Total Hip And Knee Arthroplasty Procedures - marketscreener.com

Apr 13, 2026

Pacira (PCRX) Highlights Economic Benefits of Exparel in Orthope - GuruFocus

Apr 13, 2026

Hip replacement patients with back pain used fewer opioids with EXPAREL - Stock Titan

Apr 13, 2026

Apr 11, 2026

(PCRX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily

Apr 11, 2026

Apr 10, 2026

Investment Recap: Can Pacira BioSciences Inc expand its profit marginsWeekly Trade Report & Risk Controlled Daily Plans - baoquankhu1.vn

Apr 10, 2026

PCRX.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Apr 10, 2026

Weekly Earnings: Is Pacira BioSciences Inc stock a falling knife or bargain buy2026 Outlook & Risk Managed Investment Strategies - baoquankhu1.vn

Apr 10, 2026

PCRX.O Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 10, 2026

Apr 09, 2026

Dimensional Fund Advisors (NASDAQ: PCRX) reports 2.06M shares owned - Stock Titan

Apr 09, 2026

Pacira BioSciences to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference - The Manila Times

Apr 08, 2026

Pacira investors get live access to Needham healthcare event April 15 - Stock Titan

Apr 08, 2026

Apr 07, 2026

Pacira (PCRX) BioSciences well-positioned with genicular outcomes registry evidence - MSN

Apr 07, 2026

Apr 05, 2026

2026-04-05 | Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Stockholders to Inquire about Securities Investigation | NDAQ:PCRX | Press Release - Stockhouse

Apr 05, 2026

Apr 04, 2026

PCRX Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 04, 2026

Apr 03, 2026

PCRX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Apr 03, 2026

Apr 02, 2026

2026-04-02 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Investors to Learn More About the Investigation | NDAQ:PCRX | Press Release - Stockhouse

Apr 02, 2026